TargetBeta
ROR1
ROR family WNT receptor 1 · also NTRKR1 · I-set domain containing
5 programs in company-led studies act on ROR1, from 5 companies: 1 in phase 3. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (3 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| zilovertamab vedotin | Merck | phase 3 | 107 running | – | a judged reading |
| Anti-ROR1/Anti-CD3 Bispecific Antibody EMB-07rule | Shanghai EpimAb Biotherapeutics | phase 2 | 22 running | CD3E | NCIt |
| TQB2101 | Sino Biopharmaceutical | phase 1 | 22 running | – | the company's pipeline |
| Anti-B7-H3/Anti-ROR1-Exatecan Bispecific Antibody-drug Conjugate NEOK001rule | NEOK Bio | phase 1 | 11 running | CD276 | NCIt |
| Anti-ROR1 Antibody-drug Conjugate IM-1021rule | Immunome | phase 1 | 11 running | – | NCIt |
Conditions their studies are in
- Breast Neoplasms, 1 program
- Burkitt Lymphoma, 1 program
- Carcinoma, Transitional Cell, 1 program
- Hematologic Neoplasms, 1 program
- Leukemia, Lymphocytic, Chronic, B-Cell, 1 program
- Lymphoma, 1 program
- Lymphoma, Large B-Cell, Diffuse, 1 program
- Neoplasm Metastasis, 1 program
- Triple Negative Breast Neoplasms, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Sep 24, 2027zilovertamab vedotin · Merck · phase 3 · NCT05139017
- May 2028Anti-ROR1 Antibody-drug Conjugate IM-1021 · Immunome · phase 1 · NCT06823167
- Jun 30, 2028Anti-ROR1/Anti-CD3 Bispecific Antibody EMB-07 · Shanghai EpimAb Biotherapeutics · phase 2 · NCT07432022
- Jan 2029Anti-B7-H3/Anti-ROR1-Exatecan Bispecific Antibody-drug Conjugate NEOK001 · NEOK Bio · phase 1 · NCT07612176
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.